Vesicle dispersion and cosmetic

The vesicle dispersion with specific components ensures stability and transparency of oil-soluble agents in cosmetics, enhancing user experience through optimized formulation.

JP7750656B2Active Publication Date: 2025-10-07CBON
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
JP2021025221
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2021-02-19
Publication Date
2025-10-07
Estimated Expiration
2041-02-19

AI Technical Summary

Technical Problem

Existing cosmetic formulations containing oil-soluble agents like astaxanthin and tocopherol face stability issues, leading to cloudiness and poor dispersion, affecting aesthetic appearance and user experience.

Method used

A vesicle dispersion comprising water, pentylene glycol, a compound with lecithin and phytosterols, and surfactants like polyoxyethylene hydrogenated castor oil or polyglyceryl isostearate, optimized to maintain transparency and provide a pleasant feel.

Benefits of technology

The vesicle dispersion achieves excellent stability and skin permeability while maintaining transparency, with a pleasant feel, even at varying temperatures.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007750656000001
    Figure 0007750656000001
  • Figure 0007750656000002
    Figure 0007750656000002
  • Figure 0007750656000003
    Figure 0007750656000003
Patent Text Reader

Abstract

To provide a vesicle dispersion that contains an oil-based component containing a functional oil solution but yet offers excellent stability and usability, and cosmetics containing the vesicle dispersion.SOLUTION: A vesicle dispersion contains (A) water, (B) 3 wt.% or more of pentyleneglycol, (C) 0.55 wt.% or more and 0.9 wt.% or less of a compound containing lecithin and phytosterols, (D) an oil solution, and (E) polyoxyethylene hardened castor oil or polyglycerol isostearate.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] The present invention relates to a vesicle dispersion and a cosmetic preparation containing the vesicle dispersion. [Background technology]

[0002] Vesicles are small reticulum bodies consisting of bilayer membranes formed by amphiphilic lipids, surfactants, etc. Vesicles are characterized by their ability to encapsulate water-soluble and oil-soluble substances, and have been used as drug carriers in drug delivery systems, etc.

[0003] Cosmetics and other products often contain oil-soluble agents such as astaxanthin and tocopherol for their beneficial effects on the skin. However, these oil-soluble substances have stability issues when blended into lotions and other products, such as causing cloudiness and impairing the aesthetic appearance, or having poor dispersion stability and separating over time.

[0004] In order to solve these problems, Patent Document 1 discloses the development of a translucent or transparent cosmetic that has excellent stability and provides noticeable effects such as a feeling of penetration, no stickiness, and softness of the skin after application.

[0005] However, even with the embodiment proposed in Patent Document 1, it was difficult to obtain a vesicle dispersion that contained an oily component including a functional oil agent and yet had excellent stability and a pleasant feel when used. [Prior art documents] [Patent documents]

[0006] [Patent Document 1] Japanese Patent Application Laid-Open No. 2011-136934 Summary of the Invention [Problem to be solved by the invention]

[0007] The present invention provides a vesicle dispersion that contains an oily component including a functional oil agent, yet has excellent stability and a pleasant feel when used, and a cosmetic preparation containing the vesicle dispersion. [Means for solving the problem]

[0008] The vesicle dispersion according to the present invention comprises: (A) water, (B) 3% by weight or more of pentylene glycol; (C) a compound containing 0.55% by weight or more and 0.9% by weight or less of lecithin and phytosterols; (D) functional oils, and (E) Polyoxyethylene hydrogenated castor oil or polyglyceryl isostearate may include:

[0009] In the vesicle dispersion according to the present invention, Component (E) may contain hydrophilic polyoxyethylene hydrogenated castor oil or polyglyceryl isostearate having an HLB of 10 or more.

[0010] In the vesicle dispersion according to the present invention, When polyoxyethylene hydrogenated castor oil is used as component (E), the polyoxyethylene hydrogenated castor oil may be PEG-60 hydrogenated castor oil.

[0011] In the vesicle dispersion according to the present invention, When polyglyceryl isostearate is used as component (E), the polyglyceryl isostearate may be polyglyceryl-10 isostearate.

[0012] In the vesicle dispersion according to the present invention, The oil is a compound containing astaxanthin and caprylic / capric triglyceride, The compound containing astaxanthin and caprylic / capric triglyceride may be contained in an amount of 0.4% by weight or less.

[0013] In the vesicle dispersion according to the present invention, Polyoxyethylene hydrogenated castor oil or polyglyceryl isostearate may be contained in an amount of 0.75% by weight or more and 2.5% by weight or less.

[0014] The cosmetic composition according to the present invention comprises: The cosmetic composition may contain the above-mentioned vesicle dispersion. [Effects of the Invention]

[0015] According to the present invention, it is possible to provide a vesicle dispersion that contains an oily component including a functional oil agent, yet has excellent stability and a pleasant feel when used, and a cosmetic preparation containing the vesicle dispersion. DETAILED DESCRIPTION OF THE INVENTION

[0016] The vesicle dispersion of this embodiment may contain water, pentylene glycol, a compound containing lecithin and phytosterols as an amphiphilic substance, an oil, and polyoxyethylene hydrogenated castor oil or polyglyceryl isostearate as a surfactant.

[0017] In the vesicle dispersion, pentylene glycol may be contained at 3% by weight or more, preferably 4% by weight or more, and more preferably 5% by weight or more. A low pentylene glycol content can cause problems with transparency and stability over time after formulation. The upper limit of pentylene glycol can be 60% by weight, and more specifically, 50% by weight. Note that fine particles increase transparency, while large particles decrease transparency. This embodiment is superior in that it can maintain transparency while containing a large amount of oil and achieve fine particles. By achieving such fine particles, high skin permeability can be achieved.

[0018] The vesicle dispersion may contain 0.55% by weight or more of the compound containing lecithin and phytosterols, preferably 0.6% by weight or more. The vesicle dispersion may contain 0.9% by weight or less of the compound containing lecithin and phytosterols, preferably 0.8% by weight or less. If the content of the compound containing lecithin and phytosterols is too low or too high, problems with stability over time may occur. Furthermore, if the content of the compound containing lecithin and phytosterols is too high, transparency may be poor.

[0019] In the vesicle dispersion, the oil containing a functional substance (functional oil) may be contained in an amount of less than 0.5 wt %. As long as it functions as a functional substance, there is no problem, so there is no particular lower limit. However, as an example, the oil containing a functional substance (functional oil) may be contained in an amount of 0.01 wt % or more. Examples of oils include ester oils, hydrocarbon oils, silicone oils, and animal and vegetable oils and fats. Examples of ester oils include fatty acid esters such as caprylic / capric triglyceride, cetyl ethylhexanoate, isotridecyl isononanoate, isopropyl myristate, isocetyl myristate, octyldodecyl myristate, isopropyl palmitate, ethylhexyl palmitate, butyl stearate, ethylhexyl stearate, isotridecyl stearate, methyl oleate, ethyl oleate, isobutyl oleate, triethylhexanoin, diisopropyl adipate, and diethyl sebacate. Examples of hydrocarbon oils include squalane, liquid paraffin, isoparaffin, vaseline, paraffin wax, ceresin, and microcrystalline wax.

[0020] When the oil containing a functional substance (functional oil) is a compound containing astaxanthin and caprylic / capric triglyceride, it is preferably contained at 0.4% by weight or less, and more preferably at 0.3% by weight or less. Excessive oil content can cause problems with stability over time. Astaxanthin is an example of a functional substance and is not particularly limited. Functional substances may also be used, such as tocopherol and ceramide, instead of astaxanthin. Other functional substances that may be used include carotenoids such as β-carotene, zeaxanthin, lycopene, and lutein; oil-soluble vitamins and their derivatives such as retinol and tocotrienol; ubiquinones such as coenzyme Q10; UV protection agents such as 2-ethylhexyl paramethoxycinnamate; isoflavones, anthocyanins; polyphenols such as chlorogenic acid, ferulic acid, gallic acid, and proanthocyanidin; fragrances; plant extracts; proteins; and sphingolipids such as ceramide.

[0021] When polyoxyethylene hydrogenated castor oil is contained, the polyoxyethylene hydrogenated castor oil is contained in the vesicle dispersion preferably at 0.75 wt% or more, more preferably at 1.0 wt% or more, and preferably at 2.5 wt% or less, more preferably at 2.3 wt% or less, and even more preferably at 2.0 wt% or less.

[0022] When polyglyceryl isostearate is contained, the vesicle dispersion preferably contains 0.75 wt% or more, more preferably 1.0 wt% or more of polyglyceryl isostearate, and the vesicle dispersion preferably contains 2.5 wt% or less, more preferably 2.3 wt% or less, and even more preferably 2.0 wt% or less of polyglyceryl isostearate.

[0023] If the content of polyoxyethylene hydrogenated castor oil or polyglyceryl isostearate is too low, problems with stability over time may occur, whereas if the content of polyoxyethylene hydrogenated castor oil or polyglyceryl isostearate is too high, problems with stability over time may occur and transparency may also be impaired.

[0024] As the polyoxyethylene hydrogenated castor oil, it is preferable to use a hydrophilic polyoxyethylene hydrogenated castor oil having an HLB of 10 or more. As the polyoxyethylene hydrogenated castor oil, hydrogenated castor oil may be used, such as PEG-30 hydrogenated castor oil, PEG-40 hydrogenated castor oil, PEG-60 hydrogenated castor oil, PEG-70 hydrogenated castor oil, PEG-80 hydrogenated castor oil, or PEG-100 hydrogenated castor oil. However, it is preferable to use PEG-60 hydrogenated castor oil. As the polyglyceryl isostearate, it is possible to use a hydrophilic polyglyceryl isostearate having an HLB of 10 or more. Examples of polyglyceryl isostearate that may be used include polyglyceryl-5 isostearate, polyglyceryl-6 isostearate, polyglyceryl-7 isostearate, polyglyceryl-8 isostearate, polyglyceryl-9 isostearate, polyglyceryl-10 isostearate, and polyglyceryl-20 isostearate. However, it is preferable to use polyglyceryl-10 isostearate.

[0025] The cosmetic according to the present embodiment may contain components such as additives, etc. Examples of such additives include thickeners, surfactants, preservatives, pH adjusters, chelating agents, stabilizers, irritation reducers, antiseptics, colorants, dispersants, fragrances, antioxidants, plant extracts, vitamins, and amino acids.

[0026] [Examples and Comparative Examples] Next, examples and comparative examples will be described.

[0027] Vesicle dispersions in the examples and comparative examples were prepared as follows.

[0028] First, component D (caprylic / capric triglyceride) and component E (PEG-60 hydrogenated castor oil, polyglyceryl-10 isostearate, PEG-20 sorbitan cocoate, or polyglyceryl-10 stearate) were heated and mixed at 75°C to 85°C to prepare a uniform first solution.

[0029] Furthermore, component B (pentylene glycol or BG) and component C (a compound containing hydrogenated lecithin and phytosterols or a compound containing hydrogenated lecithin and cholesterol) were mixed under heating at 75°C to 85°C to prepare a homogeneous second solution.

[0030] Next, the first solution was added to the second solution with stirring, and the mixture was heated and mixed at 75°C to 85°C to prepare a homogeneous third solution.

[0031] Next, the third solution was added to purified water heated to 75° C. to 85° C. with stirring, and the mixture was heated and mixed at 75° C. to 85° C. Thereafter, the solution was cooled to room temperature with stirring to obtain a vesicle dispersion.

[0032] Components D and E were added to a solution containing components B and C, and mixed at 75° C. to 85° C. until uniform, then cooled to room temperature.

[0033] The evaluation methods used in the examples and comparative examples are as follows: Usually, when preparing a vesicle dispersion, special equipment capable of applying high energy, such as a high-pressure homogenizer or an ultrasonic disperser, is used, but in the vesicle dispersion according to the examples of the present invention, it is possible to obtain fine vesicles even with a homomixer, which is a very beneficial result. (Method for evaluating transparency immediately after preparation) The container was sealed in a 70 mL transparent glass container and left to stand at room temperature of 20 to 25°C. A piece of paper with letters printed on it was placed behind the container, and when viewed from a horizontal direction, the container was evaluated based on whether the letters were clearly visible. 3: The text is clearly readable 2: The text appears slightly blurry 1: The text is blurry and difficult to read

[0034] (Method for evaluating stability over time) The samples were sealed in transparent glass containers and left to stand at a constant temperature. The degree of change from the initial state was evaluated by visual observation. ⊚: There is almost no change in transparency from the initial stage, and no separation or precipitation is observed. ○: A slight decrease in transparency is observed, or slight separation or precipitation is observed, or both. △: A clear decrease in transparency is observed, or there is a lot of separation or precipitation, or both. ×: Significant decrease in transparency is observed, or the degree of separation or precipitation is large, or both.

[0035] (Method for evaluating penetration sensation) Five expert panelists applied the prescribed amount of 1.5 mL to the face and rated the penetration sensation on a 5-point scale (5: very noticeable, 4: somewhat noticeable, 3: average, 2: not noticeable, 1: not noticeable). The scores were averaged and rated on a 4-point scale. ◎: 4.5 or higher ○: 3.5 or more and less than 4.5 △: 2.5 or more and less than 3.5 ×: Less than 2.5

[0036] As shown in Table 1 below, it was confirmed that when pentylene glycol is contained at 5% by weight or more, there are no problems with transparency, stability over time, or penetration. In particular, it was confirmed that when the content is 5% by weight or more and 10% by weight or less, excellent stability over time is also exhibited at a low temperature of 5°C. It is also beneficial that the stability can be maintained even in low temperatures such as a bathroom in winter. It is also beneficial that the stability can be maintained even in thick summer conditions. [Table 1]

[0037] As shown in Table 2 below, BG was unable to provide the same effects as when pentylene glycol was used. In particular, it was confirmed that the stability over time and transparency at a low temperature of 5°C were inferior to when pentylene glycol was used. It was also confirmed that even when BG was included, excellent effects could be obtained by using pentylene glycol (see Example 6). [Table 2]

[0038] As shown in Table 3 below, it was confirmed that there were no problems with transparency, stability over time, or penetration sensation when the compound containing hydrogenated lecithin and phytosterols was contained in an amount of 0.6% by weight or more and 0.8% by weight or less. On the other hand, it was confirmed that when the content of the compound containing hydrogenated lecithin and phytosterols was 0.5% by weight or less, problems occurred with stability over time at low temperatures, and when the content of the compound containing lecithin and phytosterols was 1% by weight or more, problems occurred with stability over time at room temperature (25°C) and at low temperatures. [Table 3]

[0039] As shown in Table 4 below, it was confirmed that problems with stability over time at low temperatures occur when a compound containing astaxanthin and caprylic / capric triglyceride, an example of an oil, is contained at 0.5% by weight or more. Furthermore, it was confirmed that problems with stability over time at low temperatures occur when a compound containing hydrogenated lecithin and cholesterol is used instead of a compound containing hydrogenated lecithin and phytosterols, even when the content of the compound containing astaxanthin and caprylic / capric triglyceride is 0.2% by weight. [Table 4]

[0040] As shown in Table 5 below, it was confirmed that problems with stability over time at low temperatures occurred when the content of PEG-60 hydrogenated castor oil was 0.5 wt% or less or 3 wt% or more. It was also confirmed that no problems occurred when polyglyceryl-10 isostearate was used instead of PEG-60 hydrogenated castor oil. On the other hand, it was confirmed that problems with stability over time occurred at room temperature and low temperatures when PEG-20 sorbitan cocoate or polyglyceryl-10 stearate was used instead of PEG-60 hydrogenated castor oil. [Table 5]

[0041] The raw materials used in the examples and comparative examples are as follows: (About component B) Pentylene glycol Raw material name: Hydrolite (registered trademark) 5 green (Symrise Co., Ltd.) BG Raw material name: 1,3 Butylene Glycol (13BGUK) (Daicel Corporation) (About component C) Hydrogenated lecithin: Phytosterols Ingredient name: Phytopresome (Nippon Fine Chemical Co., Ltd.) The ratio of hydrogenated lecithin to phytosterols is 85.7:14.3. Hydrogenated lecithin: cholesterol Raw material name: Presome CS2-101 (Nippon Fine Chemical Co., Ltd.) The ratio of hydrogenated lecithin to cholesterol is 80:20. The hydrogenated lecithin and the sterols may be mixed separately, or may be mixed uniformly in advance before use. (About component D) Astaxanthin: Caprylic / Capric Triglyceride Ingredient Name: Astax-ST (Marine Daioh Co., Ltd.) The ratio of astaxanthin to tri(caprylic / capric acid)glyceryl is 5:95. Astaxanthin and caprylic / capric triglyceride may be mixed individually or may be mixed uniformly in advance before use. (About ingredient E) PEG-60 Hydrogenated Castor Oil Raw Material Name: Emanon CH-60(K) (Kao Corporation) Polyglyceryl-10 Isostearate Ingredient Name: S Face 10G-IS (Sakamoto Pharmaceutical Co., Ltd.) PEG-20 sorbitan cocoate Raw material name: Leodor Super TW-L120 (Kao Corporation) Polyglyceryl-10 stearate Raw material name: Decaglyn 1-SV (Nippon Surfactant Industry Co., Ltd.)

[0042] The vesicle dispersion according to this embodiment can be incorporated into cosmetics. The content may be 100% by weight, and cosmetics comprising the vesicle dispersion can also be provided. The lower limit is not particularly limited, but may be, for example, 0.01% by weight, 0.1% by weight or more, or 1% by weight or more. As an example, the formulation of a cosmetic is shown below. For example, the vesicle dispersion according to Example 1 can be used.

[0043] (lotion) JPEG0007750656000006.jpg169127

[0044] (Beauty serum) JPEG0007750656000007.jpg178127

[0045] (cream) JPEG0007750656000008.jpg199132

[0046] The above-mentioned embodiments and examples are merely examples for explaining the invention described in the claims. Furthermore, the claims as originally filed may be modified as appropriate within the scope of the patent specification, and the scope may be expanded or modified.

Claims

1. (A) water, (B) 3% by weight or more of pentylene glycol; (C) lecithin and phytosterols, (D) less than 0.5 wt. % of a functional oil; and (E) 0.75% by weight or more but less than 3% by weight of polyoxyethylene hydrogenated castor oil or polyglyceryl isostearate Including, A vesicle dispersion having a total content of lecithin and phytosterols of 0.55% by weight or more and 0.9% by weight or less.

2. 2. The vesicle dispersion according to claim 1, comprising, as component (E), hydrophilic polyoxyethylene hydrogenated castor oil or polyglyceryl isostearate having an HLB of 10 or more.

3. 3. The vesicle dispersion according to claim 1, wherein when polyoxyethylene hydrogenated castor oil is used as component (E), the polyoxyethylene hydrogenated castor oil is PEG-60 hydrogenated castor oil.

4. 3. The vesicle dispersion according to claim 1, wherein when polyglyceryl isostearate is used as component (E), the polyglyceryl isostearate is polyglyceryl-10 isostearate.

5. The functional oil contains astaxanthin and caprylic / capric triglyceride; 5. The vesicle dispersion according to claim 1, wherein the total content of astaxanthin and caprylic / capric triglyceride is 0.4% by weight or less.

6. 6. The vesicle dispersion according to claim 1, wherein the polyoxyethylene hydrogenated castor oil or polyglyceryl isostearate is contained in an amount of 2.5% by weight or less.

7. A cosmetic preparation comprising the vesicle dispersion according to any one of claims 1 to 6.

Citation Information

Patent Citations

  • Preparation having liquid crystal structure

    JP2004331594A

  • Cosmetic

    JP2011136934A

  • Diester composition having lamella-formability for cosmetic or skin external preparation

    JP2013049633A

  • Liposome composition incorporated with ascorbic acid derivative

    JP2013209320A

  • Cosmetic

    JP2016044150A